Target intelligence / Profile preview

Immunoglobulin lambda variable (I)-20 (pseudogene) (IGLVI-20)

Target
IGLVI-20
Molecular classification
Other (Pseudogene, Immunoglobulin light chain variable region family)
01

Overview

IGLVI-20 (Immunoglobulin lambda variable (I)-20) is a pseudogene within the immunoglobulin lambda light chain variable region locus on human chromosome 22[3][5]. It is part of the family of genes responsible for the diversity of human antibody light chains but does not encode a functional protein due to its classification as a pseudogene. Functional variable region lambda genes are critical for antibody diversity and antigen recognition, but pseudogenes like IGLVI-20 contribute only indirectly through mechanisms such as gene conversion or recombination in some cases, though for most purposes, they are nonfunctional. "Immunoglobulin lambda variable" genes in general contribute to the specificity and diversity of the adaptive immune response, but IGLVI-20 itself does not encode a functional product and is not considered a therapeutic target[3][5]. Notable points: - The "immunoglobulin lambda variable" gene families include many variable gene segments; only a subset are functional, and IGLVI-20 is a pseudogene[2][5]. - As a pseudogene, IGLVI-20 is not referenced in the literature as a drug or therapeutic target, nor is it involved in known disease pathways or drug interactions[3][5]. - Confusion about targeting may arise from misreading the IG lambda locus, where only functional genes produce light chain proteins involved in B cell receptor and antibody formation[1][2]. - In structured databases and gene summaries, it is explicitly annotated as a pseudogene[3][5].

Other names
IGLV(I)-20IGLVI20V1-6P

Beyond the preview

Go deeper on Immunoglobulin lambda variable (I)-20 (pseudogene) (IGLVI-20).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda variable (I)-20 (pseudogene) (IGLVI-20).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call